Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

'Total Disaster' In First-Line Lung Cancer For BMS's Opdivo

Executive Summary

Things couldn't have gone any worse for Bristol-Myers Squibb's Opdivo in the CheckMate 026 lung cancer data presented at ESMO. Without even a trend towards efficacy in patients with high levels of PD-L1 expression, imminent erosion of market share by Merck's Keytruda seems inevitable.

Advertisement

Related Content

Keeping Track: Immuno-Oncology Racks Up More Approvals; Bar Still Too High For Advair Generics
Bristol's New CSO Lynch Defends Lung Cancer Plans, Proclaims R&D Priorities
CHMP Opinions: Opdivo Sees Keytruda's Hodgkin's And Raises It Head & Neck
Bristol Changes Up R&D But Not Backing Down On Oncology
BMS M&A Q&A: Is IO Player Now In Play? Lung Cancer Moves Seen As Key
NSCLC Momentum Goes To Merck And Roche, Bodes Well For Combinations
4Q Pharma Results Preview, Part 2: Pfizer, Lilly, Roche, AstraZeneca, Merck, Amgen, Novo
ESMO Preview: Opdivo Under Pressure
Does CheckMate 026 Take Bristol Out Of The End Game?
What's Next For Bristol's Opdivo/Yervoy Combination

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097450

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel